THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY

Robert Lafyatis, Robert Spiera, Robin Domsic, Anna Papazoglou, Colin Ligon, Christina Morse, J.F. Denis, Mat D. Davis, Tina Gruosso, Gabriel Tremblay, Matthew McCourt, Sandra Sinclair, J. Delara, K. Alvarado, Debra L. Wood, Paul I. Nadler, Elizabeth R. Volkmann